Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies

Antispike monoclonal antibody treatment of 180 B-cell-depleted patients with mild-to-moderate coronavirus disease 2019 (COVID-19) resulted in good outcomes overall, with only 12.2% progressing to severe disease, 9.4% requiring hospitalization, 0.6% requiring mechanical ventilation, no deaths within...

Descripción completa

Detalles Bibliográficos
Autores principales: Yetmar, Zachary A, Khodadadi, Ryan B, Seville, Maria Teresa, Brumble, Lisa, O’Horo, John C, Ganesh, Ravindra, Razonable, Raymund R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047222/
https://www.ncbi.nlm.nih.gov/pubmed/35791358
http://dx.doi.org/10.1093/ofid/ofac204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047222/
https://www.ncbi.nlm.nih.gov/pubmed/35791358
http://dx.doi.org/10.1093/ofid/ofac204

Ejemplares similares